Clinician scientist
Doherty Institute, University of Melbourne
Disclosure(s): No financial relationships to disclose
Steven trained in infectious diseases in Melbourne (2004-2005) and Darwin (2006) and was awarded a PhD from the Menzies School of Health Research/Charles Darwin University in 2010. His post-doctoral training took him to Duke University, North Carolina (2011) and the Wellcome Trust Sanger Institute, Cambridge in the UK (2012). Key achievements from his research include the discovery and naming of two new species of Staphylococcus, discovery of a novel genotype of hepatitis B in Indigenous Australians, and the conduct of clinical trials for the treatment of impetigo and MRSA bloodstream infections. He led the CAMERA2 trial and is the lead PI for the Staphylococcus aureus Network Adaptive Platform (SNAP) trial and the Australasian COVID-19 Trial (ASCOT).